

# Minutes UK BMT Pharmacists Group Committee Meeting

Friday 21st May 2021, 4-5pm, via Zoom

Present – Raakhee Shah (RS), Liz Davies (LD), Nick Duncan (ND), Nadjoua Maouche (NM), Helen Scarfe (HS), Sinead Smith (SS)

#### 1. Terms of References

Updated draft was reviewed. It was agreed to add an additional sentence relating to the role of the group in supporting the delivery of HSCT services. **Action – LD to update document.** 

It was agreed that a conflict of interest form was required for committee members. **Action – ND to produce form.** 

# 2. Education and Training

NM has produced a spreadsheet summarising topics included in previous educational meetings and suggesting potential topics for future meetings. ND confirmed that the meetings usually contain 4-5 slots and it was suggested that the following subject headings could be used as a framework:

- JACIE competencies
- Disease topic
- Audit and Research
- IECs

It was also agreed that the group should aim to increase the number of pharmacist speakers for future meetings.

There was a discussion about specific topics for the next meeting and the following were suggested as first choice topics:

Topic	Potential speaker	Comments
Post Transplant Strategies in AML	Charles Craddock	ND can invite
Management of VOD	Pharmacist speaker	To canvas group for potential
		speakers
Transplantation for sickle cell	??	RS to enquire re potential
disease		speakers
Adoptive T-cell therapy for EBV-	Anne Black (technical)	
driven lymphomas, technical and	Sridhar Chaganti (clinical)	
clinical aspects		
Investigation(s) of melphalan	Raakhee Shah	As part of Audit and Research
timings in transplant patients	Helen Scarfe / Siobhan Smith	stream

It was also suggested that a potential topic under the IEC umbrella could be the management of out of specification CAR-T products as that is a hot-topic at present Friday 24<sup>th</sup> September (via Zoom) was agreed on as the provisional date for the next educational meeting, provided it doesn't clash with any other haematology meetings. **Action – NM to check calendar for potential clashes** 





In relation to the e-learning modules ND stated that he has contacted Charlie Clark, who has been leading on the process to date, to find out how involved she wishes to be with future developments. Once he has spoken to Charlie it should be possible to devise a work-plan for future modules. **Action – ND to follow-up and liaise with NM re work-plan.** 

# 3. e-mail group / BOPA website update

It was agreed that details of the new committee structure plus finalised Terms of Reference should be communicated to the wider group via the groups.io email platform. The group's page on the BOPA website should also be updated to include details of the committee plus co-chair biographies. It was agreed that it would also be useful to provide details of the functions of the group (particularly the email platform) and details of who to contact to join the group. Actions – ND to send email and liaise with BOPA once Terms of Reference are finalised.

## 4. Audit and Research update

It was agreed that HS and SS will ask transplant centres to provide details of ongoing or planned audit and research projects, with the aim of developing a spreadsheet that can be shared with the group with the aim of promoting collaborative working in his area.

RS is auditing a recent change in practice at UCLH in relation to the time interval between melphalan administration and stem cell return. It was agreed that this continues to be a contentious issue and ND suggested that HS and SS may wish to undertake a survey of practice in UK transplant centres – this could be submitted to BOPA and presented at the next education meeting. **Action – HS and SS to look into developing survey.** 

### 5. AOB

The recently published draft NHSE service specification for the delivery of CAR-T Therapy was discussed. ND confirmed that BOPA had suggested that the UK BMT Pharmacists' Group would be well placed to comment on this document on behalf of BOPA. There was some discussion about the content of the specification and it was agreed that RS would liaise with Jackie Chappell and Sumi Gabriel (co-chairs of the Pan UK ATTC Pharmacy Working Group – Clinical Subgroup) and would collate responses and feedback to BOPA by Friday 28<sup>th</sup> May (final deadline is 31<sup>st</sup> May). **Action – RS to feedback to BOPA.** 

## **Date of Next Meeting**

wb 6<sup>th</sup> September – ND to send out Doodle poll to confirm date

